STAT lists three main issues in vaccine policy for 2026: funding and supply contracts, storage and expiry of vaccines, and regulatory/legal frameworks for future pandemics[1]. The European Commission has extended the second phase of vaccine supply contracts until the end of 2026, which means that large quantities of vaccines will be delivered in phases until 2026 and must be stored by Member States[1]. The extension of the delivery dates has also adjusted the expiry dates of some vaccines, which is intended to reduce the pressure to use stocks immediately[1]. This leads to the need to address storage costs and the risk of wastage, as the state will pay for some vaccines in years when they may not be fully used[1]. Issues of transparency of public spending and control of vaccine purchases are also highlighted, including the powers of regulatory authorities to review purchases and storage[1]. These points, according to STAT, create key policy and logistical challenges to watch in 2026[1].